Home > Resources > Publications > Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study.
Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study.
Targeted optical fluorescence imaging: a meta‑narrative review and future perspectives.
Schouw, H. M., Huisman, L. A., Janssen, Y. F., Slart, R. H. J. A., Borra, R. J. H., Willemsen, A. T. M., Brouwers, A. H., van Dijl, J. M., Dierckx, R. A., van Dam, G. M., Szymanski, W., Boersma, H. H., Kruijff, S. European Journal Of Nuclear Medicine And Molecular Imaging. doi: 10.1007/s00259-021-05504-y
Personalized type 2 diabetes treatment in primary care: insights using real world data
Martina Ambrož - Personalized type 2 diabetes treatment in primary care: insights using real world data.
This thesis examines personalized treatment for individuals with type 2 diabetes (T2D) in primary care. We studied glycated hemoglobin A1c (HbA1c) and systolic blood pressure (SBP) levels at the start of glucose- and blood pressure-lowering medication between 2007 and 2020. Surprisingly, no significant differences were found based on age or frailty, highlighting a lack of personalized treatment. Another study revealed more hypotension-related adverse events in older patients, those with polypharmacy, and lower SBP levels, emphasizing the need for tailored approaches. Sex differences in medication prescribing were identified, with females less likely to receive certain medications. Females with T2D also showed age-specific variations in LDL cholesterol levels, suggesting the need for sex-specific treatment recommendations. Additionally, patients' willingness to engage in different treatments varied, with only half open to all options. These findings underscore the importance of personalized approaches in T2D treatment, requiring attention in clinical practice and future research.
Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers.
Koller M, Qiu SQ, Linssen MD, Jansen L, Kelder W, de Vries J, Kruithof I, Zhang GJ, Robinson DJ, Nagengast WB, Jorritsma-Smit A, van der Vegt B, van Dam GM. Nat Commun. 2018 Sep 18;9(1):3739. doi: 10.1038/s41467-018-05727-y. PubMed PMID: 30228269; PubMed Central PMCID: PMC6143516.
We use cookies to optimize your experience and analyze traffic on our website. By clicking 'Accept all,' you consent to the use of all cookies. You can customize your preferences by clicking on 'Settings' or read our privacy policy for more information.
Essential cookies
These cookies make sure the website functions properly. These cookies also provide us to anonymously monitor website statistics. Because these cookies are essential for the website, you can not disable them without compromising the functionality of the website.
Analytical cookies
These cookies collect data that we use to understand how our website is used and perceived. These cookies also help us to optimize the website for the best user experience.
Advertising cookies
These cookies allow ad-networks to monitor your online behaviour so they can display relevant ads based on your interest and online behaviour. These cookies also prevent the same ads from being displayed over and over.
